title: The development of pulmonary embolus in patients with haemophilia A and high-titre inhibitors - a case series and review of the literature.
authors: Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.
authors: M S
authors: MS
authors: Silvey
authors: Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.
authors: S L
authors: SL
authors: Carpenter
authors: Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA.
authors: B M
authors: BM
authors: Wicklund
mesh_terms: D002648:Child; D002675:Child, Preschool; D005169:Factor VIII / Q000276:immunology* / Q000627:therapeutic use; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007223:Infant; D007518:Isoantibodies / Q000276:immunology*; D008297:Male; D011655:Pulmonary Embolism / Q000175:diagnosis* / Q000209:etiology*; D014057:Tomography, X-Ray Computed
chemical_list: D007518:Isoantibodies; D005169:Factor VIII
references: Kreuz W, Ettingshausen CE, Auerswald G et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04
references: Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
references: Lusher JM, Shapiro SS, Palascak JE. Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med 1980; 303: 421-5.
references: Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
references: Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparison (FENOC) Study. Blood 2007; 109: 546-51.
references: Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Hemophilia 2002; 8: 83-90.
references: Roberts H. Recombinant factor VIIa (NovoSeven)and the safety of treatment. Semin Hematol 2001; 38: 48-50.
references: Coppola A, Franchini M, Makris M, Santagostino E, Di Minno G, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia 2012; 18: e173-87.
references: Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.